JP2022518463A5 - - Google Patents

Info

Publication number
JP2022518463A5
JP2022518463A5 JP2021541429A JP2021541429A JP2022518463A5 JP 2022518463 A5 JP2022518463 A5 JP 2022518463A5 JP 2021541429 A JP2021541429 A JP 2021541429A JP 2021541429 A JP2021541429 A JP 2021541429A JP 2022518463 A5 JP2022518463 A5 JP 2022518463A5
Authority
JP
Japan
Prior art keywords
immune cells
gene
nucleic acid
gene sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518463A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013964 external-priority patent/WO2020150534A2/en
Publication of JP2022518463A publication Critical patent/JP2022518463A/ja
Publication of JP2022518463A5 publication Critical patent/JP2022518463A5/ja
Priority to JP2024141710A priority Critical patent/JP2024174899A/ja
Pending legal-status Critical Current

Links

JP2021541429A 2019-01-16 2020-01-16 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞 Pending JP2022518463A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024141710A JP2024174899A (ja) 2019-01-16 2024-08-23 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962793277P 2019-01-16 2019-01-16
US62/793,277 2019-01-16
US201962839870P 2019-04-29 2019-04-29
US62/839,870 2019-04-29
PCT/US2020/013964 WO2020150534A2 (en) 2019-01-16 2020-01-16 Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024141710A Division JP2024174899A (ja) 2019-01-16 2024-08-23 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Publications (2)

Publication Number Publication Date
JP2022518463A JP2022518463A (ja) 2022-03-15
JP2022518463A5 true JP2022518463A5 (https=) 2023-01-25

Family

ID=71613446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021541429A Pending JP2022518463A (ja) 2019-01-16 2020-01-16 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞
JP2024141710A Pending JP2024174899A (ja) 2019-01-16 2024-08-23 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024141710A Pending JP2024174899A (ja) 2019-01-16 2024-08-23 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞

Country Status (9)

Country Link
US (1) US20220133790A1 (https=)
EP (1) EP3911735A4 (https=)
JP (2) JP2022518463A (https=)
KR (1) KR20210116526A (https=)
CN (1) CN114072495A (https=)
AU (1) AU2020208616A1 (https=)
CA (1) CA3126699A1 (https=)
SG (1) SG11202107555XA (https=)
WO (1) WO2020150534A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019130504A (ru) 2017-02-28 2021-03-30 Вор Байофарма, Инк. Композиции и способы ингибирования линиеспецифических белков
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
WO2020160517A1 (en) * 2019-01-31 2020-08-06 Beam Therapeutics Inc. Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
CN114981409A (zh) * 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
US20240238344A1 (en) * 2020-08-28 2024-07-18 Vor Biopharma Inc. Compositions and methods for cd123 modification
WO2022056459A1 (en) * 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd5 modification
WO2022061115A1 (en) * 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
CN116322716A (zh) * 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
CA3196831A1 (en) * 2020-09-25 2022-03-31 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
WO2022072643A1 (en) * 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
CN116801890A (zh) * 2020-11-04 2023-09-22 小利兰·斯坦福大学董事会 用于增强治疗性免疫细胞功效的方法和组合物
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4255453A4 (en) * 2020-12-03 2025-03-26 Nkarta, Inc. Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
IL303506A (en) * 2020-12-11 2023-08-01 Intellia Therapeutics Inc Polynucleotides, compositions, and methods for genome editing involving deamination
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CA3204417A1 (en) * 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
WO2022215978A1 (ko) * 2021-04-05 2022-10-13 주식회사 셀렌진 Pdcd-1 유전자에 상보적인 가이드 rna 및 이의 용도
CN113179160B (zh) * 2021-04-15 2022-03-18 中国电子科技集团公司第三十研究所 一种适用于qkd中私钥放大的最优输入码长处理方法及单元
WO2022235971A2 (en) * 2021-05-06 2022-11-10 Systems Oncology, Llc Compositions for inhibiting growth of targeted cells
BR112023023642A2 (pt) * 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
AU2022331424A1 (en) * 2021-08-16 2024-02-22 Beam Therapeutics Inc. Persistent allogeneic modified immune cells and methods of use thereof
AU2022335499A1 (en) 2021-08-27 2024-02-22 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
JP2024532382A (ja) * 2021-08-30 2024-09-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー アデノシンデアミナーゼの細胞表面発現を有するｔ細胞及びその使用
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
CN113980896B (zh) * 2021-10-27 2023-10-20 中国人民解放军军事科学院军事医学研究院 Irf1在调控间充质干细胞免疫调节作用及产品上的应用
JP2024540723A (ja) * 2021-11-03 2024-11-01 インテリア セラピューティクス，インコーポレーテッド 免疫療法のためのｃｄ３８組成物及び方法
EP4430195A4 (en) * 2021-11-12 2025-09-24 Georgia Tech Res Inst ADENOSINE DEAMINASE 1 COMPOSITIONS AND METHODS OF USE THEREOF
AU2022396533A1 (en) 2021-11-24 2024-05-02 Metagenomi Therapeutics, Inc. Endonuclease systems
WO2023114777A2 (en) * 2021-12-14 2023-06-22 The Trustees Of The University Of Pennsylvania Cd5 modified cells comprising chimeric antigen receptors (cars) for treatment of solid tumors
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
EP4532697A2 (en) * 2022-06-03 2025-04-09 Beam Therapeutics Inc. Modified regulatory t cells and methods of using the same
KR20250057777A (ko) 2022-07-25 2025-04-29 인테리우스 바이오테라퓨틱스, 인코포레이티드 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof)
JP2025529590A (ja) * 2022-09-08 2025-09-04 エイゾスバイオ、インコーポレイテッド 細胞内トランスフェクションのための新規なポリペプチド組成物
EP4587570A2 (en) * 2022-09-16 2025-07-23 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations
WO2024064642A2 (en) * 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
KR20250084940A (ko) * 2022-09-30 2025-06-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 입양 t 세포 치료를 향상시키기 위한 조성물 및 방법
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
WO2024186841A2 (en) * 2023-03-06 2024-09-12 La Jolla Institute For Immunology Nfkbid cells and methods for immunotherapy
CN121358848A (zh) * 2023-03-21 2026-01-16 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途
EP4694917A1 (en) * 2023-04-12 2026-02-18 Beam Therapeutics Inc. Modified immune effector cells with improved efficacy
EP4455157A1 (en) * 2023-04-27 2024-10-30 Fundacion Publica Andaluza Progreso Y Salud M.P.- Fps Polynuceotide for t cell specific transgene expression
AU2024274412A1 (en) * 2023-05-16 2025-12-11 Prime Medicine, Inc. Genome editing compositions targeting the b2m gene and methods of use
KR20260018068A (ko) * 2023-05-26 2026-02-06 에디타스 메디신, 인코포레이티드 Cd70 발현을 표적화하는 crispr 관련 방법 및 조성물
CN116590237B (zh) * 2023-05-29 2023-10-31 上海贝斯昂科生物科技有限公司 一种遗传修饰的自然杀伤细胞及其制备和用途
WO2025111533A1 (en) * 2023-11-22 2025-05-30 The General Hospital Corporation Car-t cells comprising a cdkn1b gene knockout and methods of use thereof
WO2025119306A1 (zh) * 2023-12-06 2025-06-12 北京齐禾生科生物科技有限公司 优化工程化t细胞的碱基编辑系统及其应用
WO2025122896A1 (en) * 2023-12-08 2025-06-12 The Trustees Of The University Of Pennsylvania Cd5 modified cells comprising heterologous tcrs and methods of using the same
WO2025238594A2 (en) * 2024-05-16 2025-11-20 Fondazione Istituto Italiano Di Tecnologia DESIGN OF SYNTHETIC miRNAS TO RESTORE THE CORRECT GENE DOSAGE OF GENES ASSOCIATED WITH T LYMPHOCYTE EXHAUSTION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170335331A1 (en) * 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
WO2016205749A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
JP7033453B2 (ja) * 2015-06-30 2022-03-10 セレクティス 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法
US20170020922A1 (en) * 2015-07-16 2017-01-26 Batu Biologics Inc. Gene editing for immunological destruction of neoplasia
IL310721B2 (en) * 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
KR20190039703A (ko) * 2016-07-05 2019-04-15 더 존스 홉킨스 유니버시티 Crispr/cas9-기반 조성물 및 망막 변성을 치료하기 위한 방법
CN108753823B (zh) * 2018-06-20 2022-09-23 李广磊 利用碱基编辑技术实现基因敲除的方法及其应用
CN108949825A (zh) * 2018-07-30 2018-12-07 苏州茂行生物科技有限公司 一种靶向her2的car-t细胞的制备方法及应用

Similar Documents

Publication Publication Date Title
JP2022518463A5 (https=)
JP2022097517A (ja) リンパ球における高レベル且つ安定な遺伝子移入のための方法
JP7114117B2 (ja) 初代造血細胞におけるタンパク質送達
CN115279398B (zh) 治疗液态癌症的组合物和方法
JP2024174899A (ja) 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞
KR20210148293A (ko) 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
JP2024531344A (ja) 持続性同種改変免疫細胞及びそれらの使用方法
EP3931322A1 (en) Improved process for dna integration using rna-guided endonucleases
CA3093840A1 (en) Lymphohematopoietic engineering using cas9 base editors
US20250090585A1 (en) Modified regulatory t cells and methods of using the same
KR20230044537A (ko) 원하는 표현형을 갖는 car t 세포의 조작 및 선택을 위한 조성물 및 방법
CN115485379A (zh) 用于体外mRNA转录的合成DNA模板
EP4419117A1 (en) Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
Tretbar et al. Non-viral vectors for chimeric antigen receptor immunotherapy
Arroyo-Olarte et al. Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer: R. Arroyo-Olarte et al.
WO2023077029A9 (en) Single cell viral integration site detection
CA3223720A1 (en) Methods and compositions for improved immunotherapies
WO2025106732A1 (en) Cellular therapies for cancer and auto-immune disorders using functional gene variants identified by base-editing screening of human t cells
IL315188A (en) Methods and compositions comprising fusion proteins for improved immunotherapies
RU2793803C2 (ru) Иммунологически отличимые варианты поверхности клеток для применения в клеточной терапии
HK40066731A (en) Protein delivery in primary hematopoietic cells
WO2025151400A1 (en) Modified immune cells with increased resistance to allorejection
WO2023105000A1 (en) Vector
CA2973884C (en) Protein delivery in primary hematopoietic cells
HK1248755B (en) Protein delivery in primary hematopoietic cells